Genome Engineering with TALE and CRISPR Systems in Neuroscience

Han B. Lee 1, Brynn N. Sundberg 2, Ashley N. Sigafoos 2 and Karl J. Clark 1, 2*

1 Neurobiology of Disease Graduate Program, Mayo Graduate School, Rochester, MN, USA, 2 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA

Recent advancement in genome engineering technology is changing the landscape of biological research and providing neuroscientists with an opportunity to develop new methodologies to ask critical research questions. This advancement is highlighted by the increased use of programmable DNA-binding agents (PDBAs) such as transcription activator-like effector (TALE) and RNA-guided clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) systems. These PDBAs fused or co-expressed with various effector domains allow precise modification of genomic sequences and gene expression levels. These technologies mirror and extend beyond classic gene targeting methods contributing to the development of novel tools for basic and clinical neuroscience. In this Review, we discuss the recent development in genome engineering and potential applications of this technology in the field of neuroscience.

Keywords: ZFN, TALE, TALEN, CRISPR, Cas9, genome engineering, neuroscience

INTRODUCTION

The relationship between genotype and phenotype is often not direct and one-to-one (Hirschhorn and Daly, 2005; Manolio et al., 2009). In clinical settings, analyzing patients' whole genome sequencing data and triaging the significance of a variant remain a challenging task (MacArthur et al., 2014; Shendure, 2014; Richards et al., 2015). This is especially the case for neural or behavioral phenotypes. Many neuropsychiatric disorders are multi-genic or multi-factorial involving complex gene-gene or gene-environment interactions (Franke et al., 2009; Sullivan et al., 2012; Dunn et al., 2015). Disease manifestations of neuronal diseases, whether neuropsychiatric or neurodegenerative, are often circuit- or neuronal population-specific making circuit-level understanding indispensable in neuroscience (Shin and Liberzon, 2009; Russo and Nestler, 2013; Shepherd, 2013). Neuronal subtypes are diverse, and each type may show distinct structural, functional, electrophysiological, and connectional properties. Different methods estimate the number of neuronal subtypes in the brain from ~100 to 1000 (Stevens, 1998; Masland, 2001, 2004; Nelson et al., 2006). Different epigenetic landscapes endow a distinct identity to each neuronal subtype that arises from a common genome within each organism. This epigenetic encoding could be the substrate in which the gene-environment interaction is consolidated (Vialou et al., 2013). Interrogating such complexity in the nervous system requires sophisticated methodologies that can manipulate each component while minimizing the perturbation of the whole system. Recently developed genome engineering technologies allow genomic perturbations with surgical precision, and these technologies are well-suited for advancing neuroscience.

There are several advantages to genome engineering technologies. First, programmable DNA-binding agents (PDBAs) can be targeted to any locus in the genome. Particularly, transcription activator-like effector (TALE) and clustered regularly interspaced short palindromic repeats...
(CRISPR)/CRISPR associated (Cas) systems can be targeted at nucleotide resolution. Second, a variety of effectors can be fused to the PDBA as a module. PDBAs fused to endonucleases make breaks in the DNA that can introduce random or targeted DNA changes when co-delivered with exogenous DNA sequences. With transcription activators and repressors, or epigenetic modifiers, gene expression can be up- or down-regulated. Using fluorescent proteins as an effector, specific genomic loci can be visualized in live cells or animals allowing for structural and organizational investigations of chromatin. Third, PDBAs can be used for therapeutic purposes with applications ranging from correcting mutations in monogenic disorders to modulating gene expression. In this Review, we discuss recent developments in genome engineering and their potential applications in the field of neuroscience. We summarize the use of PDBAs as (1) genome editing tools and (2) gene expression modulators, and discuss (3) other considerations in applying these systems in neuroscience.

**GENOME EDITING WITH CUSTOMIZABLE ENDONUCLEASES**

The field of genome engineering has developed over the past several decades. Classic gene targeting that has established mutant mouse models was the first to show that biological functions of the genes can be perturbed and studied in vivo (Evans and Kaufman, 1981; Smithies et al., 1985; Thomas and Capecchi, 1986). Around the same time, investigations into nonhomologous end joining (NHEJ) and homologous recombination (HR) were defining and uncovering DNA repair pathways (Roth and Wilson, 1985; Lehman et al., 1993; Phillips and Morgan, 1994; Hagmann et al., 1996). The biology of gene targeting and DNA repair mechanisms were gradually elucidated, uncovering critical variables for genome engineering such as linear donor DNA is more recombinogenic than circular ones (Orr-Weaver et al., 1981; Folger et al., 1982; Rong and Golic, 2001) or a DNA double-strand break (DSB) in the genome increases the rate of HR (Puchta et al., 1993; Rouet et al., 1994; Choulika et al., 1995; Smith et al., 1995). The structural studies and engineering of zinc finger protein led to the development of first programmable DNA binding agents (Pavletich and Pabo, 1991; Desjarlais and Berg, 1992; Choo and Klug, 1994; Wu et al., 1995; Kim et al., 1996; Smith et al., 2000).

**Zinc Finger Nucleases (ZFNs)**

The zinc finger nuclease (ZFN) was introduced in 1996 to address the need for more specific restriction endonucleases (Kim et al., 1996). Repeated zinc finger DNA-binding domains were fused to a FokI endonuclease domain to allow for programmable DNA sequence binding specificity as each finger motif moves along the major groove of the DNA double helix and stabilizes upon binding three matching base pairs (Kim et al., 1996).

In the early 1990s it was shown that HR increased by two to four orders of magnitude in plant and mammalian cells when a double-strand break (DSB) was introduced to the genome by the rare-cutting endonuclease, I-SceI (Puchta et al., 1993; Rouet et al., 1994; Choulika et al., 1995; Smith et al., 1995). Exploiting this, a collaboration between Chandrasegaran and Carroll labs showed that HR could be significantly increased when ZFNs made DSBs in the genome (Bibikova et al., 2001).

Subsequent refinement of ZFNs provided a template for innovation of next generation genome engineering tools–TALENs and CRISPR/Cas9. For example, modified FokI catalytic domains, which increased specificity or efficiency, were first developed for ZFN applications and later adapted for TALENs. Obligate heterodimeric versions of FokI significantly decreased off-target effects and genome toxicity caused by unintended homodimerization (Miller et al., 2007; Szczepek et al., 2007). Guo et al. used directed evolution to select for increased FokI activity, improving mutagenic efficiency by three- to six-fold (Guo et al., 2010). A zinc finger nickase system had been shown to favor homology-directed repair (HDR) without activating NHEJ repair, minimizing opportunities for errors and off-target effects (Kim et al., 2012; Ramirez et al., 2012). A nickase commonly refers to an endonuclease that generates a single-strand DNA break, nick.

ZFNs have been widely used to create animal models and are currently the only genome editing tool being utilized in clinical settings. Studies addressing diseases such as Huntington's disease (Garriga-Canut et al., 2012) and Hurler and Hunter syndromes (Sharma et al., 2015) are in pre-clinical development, and HIV treatments have reached early clinical trials (Perez et al., 2008; Wilen et al., 2011; Tebas et al., 2014; for a review, see Jo et al., 2015). ZFN research is now focused on improving delivery methods. Despite the pioneering role of ZFNs, difficulty of designing and optimizing the ZFN reagents (Greisman and Pabo, 1997) led to rapid adaptation of first TALEN and then CRISPR/Cas9 systems.

**Transcription Activator-Like Effector Nucleases (TALENs)**

The DNA-binding mechanism of TALEs was elucidated in 2009 (Boch et al., 2009; Moscou and Bogdanove, 2009), years after the discovery of TALEs as secreted proteins from the bacterial plant pathogen *Xanthomomas* (Bai et al., 2000; Yang and White, 2004; Gu et al., 2005; Kay et al., 2007; Sugio et al., 2007). Native TALEs are comprised of an N-terminal domain, central repeats of the DNA binding domain, a C-terminal segment that incorporates nuclear localization signals, and a transcriptional activation domain (Bogdanove et al., 2010). The DNA-binding domain consists of 33–35 amino acid repeats with differences at residues 12 and 13 (repeat variable di-residue; RVD). A specific RVD in the DNA-binding domain recognizes a base in the target locus, providing a structural feature to assemble predictable DNA-binding domains. The DNA binding domains of a TALE are fused to the catalytic domain of a type IIS FokI endonuclease to make a targetable TALE nuclease (TALEN; Figure 1A). To induce site-specific mutation, two individual TALEN arms, separated by a 14–20 base pair spacer region, bring FokI monomers in close proximity to dimerize and produce a targeted DSB (Figure 1A).

Several modifications to the native TALE composition and initial TALEN design have improved binding and cleavage specificity and efficiency (Christian et al., 2010; Hockemeyer et al., 2010).
FIGURE 1 | DNA-binding agents, DNA double-strand break (DSB) and repair pathways. (A) A pair of TALEN monomers bound to double-strand DNA. A TALEN monomer comprises N-terminal domain, nuclear localization signal, modular repeats that contain two highly variable amino acid residues (RVDs), C-terminal domain, and FokI endonuclease. TALENs bind to target DNA in the major groove. A pair of TALEN monomers targeted closely enable FokI dimerization to make DNA double-strand break. Cas9 protein and sgRNA form a complex. The sgRNA-Cas9 complex bind to target DNA through Watson-Crick base-pairing between the target recognition region of the sgRNA and the target DNA sequence (protospacer). The target recognition region (pink rectangle) is the RNA sequence in the sgRNA that matches the target DNA sequence (20 nt). The PAM (protospacer adjacent motif) sequence varies depending on the type of Cas protein. Streptococcus pyogenes Cas9 protein recognizes 5′-NGG-3′ sequence. (B) Targetable TALEN and CRISPR/Cas9 systems generate DNA double-strand break (DSB) at the target locus in the genome. DSBs are repaired by non-homologous end joining (NHEJ), homology-directed repair (HDR), or homologous recombination (HR). Error-prone NHEJ results in non-functional proteins or loss of protein through frameshift mutations introduced to open reading frame. HDR and HR can be used to change small sequences or tag the target gene with a reporter (e.g., green fluorescent protein). TALENs, transcription activator-like effector nucleases; NLS, nuclear localization signal; RVD, repeat variable di-residue; FokI, FokI endonuclease; N-term, N-terminal domain; C-term, C-terminal domain; CRISPR/Cas9, clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9; sgRNA, single guide RNA; PAM, protospacer adjacent motif.

et al., 2011; Li et al., 2011; Tesson et al., 2011). In an effort to improve TALEN efficiency, improved TALEN scaffolds incorporated optimized nuclear localization sequences, amino-terminal, and carboxy-terminal truncations, and assorted FokI nuclease linkers (Mussolino and Cathomen, 2012). In vitro scaffolding modifications have been studied by fusing variable C-terminal truncations to the catalytic domain of FokI to determine which variants enable efficient cleavage, the final modification of which retained only 28 or 63 of the 278 original C-terminal residues (Miller et al., 2011). Different TALEN scaffolds and native TALEs from other bacterial species continue to be tested and optimized to achieve a higher and more consistent activity of targeting genetic modifications. Our lab has used the GoldyTALEN scaffold to improve in vivo efficacy with a messenger RNA expression vector backbone (pT3TS). When using the GoldyTALEN scaffold, there was a six-fold increase in somatic gene modification, and germline modification rate increased from 17 to 71% (Bedell et al., 2012). Achieving a higher level of TALEN activity can depend on the length (base pairs) of the spacer between the two individual TALEN binding sites and the specificity of DNA binding (Ma A. C. et al., 2013a).

Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR Associated (CRISPR/Cas)

First identified in Streptococcus pyogenes, the native type II CRISPR/Cas system is a bacterial adaptive immune response and the simplest among the three CRISPR/Cas systems that requires only four Cas proteins. During exposure to foreign DNA (the acquisition phase), the type II CRISPR/Cas system incorporates a
short foreign DNA sequence (protospacer), using Cas1 and Cas2 proteins, into the bacterial genome between short palindromic repeats, thus forming a CRISPR array. The expression phase of the immune response occurs when the CRISPR locus is transcribed into a long non-coding pre-CRISPR RNA (pre-crRNA), along with its partial complement, the trans-activating CRISPR RNA (tracrRNA). The tracrRNA forms base pairs with the repeat sequences of pre-crRNA, and host RNASIII cleaves the repeat sequence to produce mature crRNAs. For DNA cleavage to occur (the interference phase), the crRNA:tracrRNA:Cas9 complex scans the invading DNA for the PAM sequence and, upon Watson-Crick base pairing between crRNA and foreign DNA, neutralizes it via a DSB (for a review, see Sorek et al., 2008; Horvath and Barrangou, 2010; Jiang and Doudna, 2015; Wright et al., 2016).

Since the CRISPR sequence was discovered in 1987 (Ishino et al., 1987), the utility of CRISPR/Cas for targeted DNA cleavage was first demonstrated in 2012 in vitro and in bacterial cells (Gasiunas et al., 2012; Jinek et al., 2012). Unique from ZFNs and TALENs, which use protein domains to recognize specific DNA sequences, the CRISPR/Cas system uses RNA-based sequence recognition (Figure 1A). The crRNA and tracrRNA in the native system were simplified into a single guide RNA (sgRNA) of approximately 100 nucleotides with a generic tetraloop secondary structure to improve ease-of-use and customizability for engineering (Jinek et al., 2012). Since the application of CRISPR/Cas systems in mammalian cells (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013b), the technology has rapidly evolved: multiplexing in the CRISPR/Cas system (Cong et al., 2013), developing a paired Cas9 nickase system (Shen et al., 2014), dimerizing the dCas9 (dead Cas9; catalytically inactive) system fused to FokI endonuclease (Tsai et al., 2014a), adding a DNA-binding domain for improved target specificity (Bolukbasi et al., 2015), or splitting Cas9 into two components for improved packaging and delivery in a viral vector and temporal control (Truong et al., 2015; Wright et al., 2015; Zetsche et al., 2015b). Other factors focus on reducing targeting limitations posed by the strict PAM recognition sequence. Different variants of Cas proteins have been shown to reduce targeting limitations (Kleinstiver et al., 2015); for example, a Cas9 ortholog, Cpf1, uses a T-rich PAM sequence (Zetsche et al., 2015a).

With these successive innovations, the CRISPR/Cas9 system has become widely adapted for genome engineering. Some of the reasons for its popularity are the constructs to produce sgRNA can be easily prepared with one cloning process, the Cas9 construct can be re-used without any modification, and targeting multiple loci (multiplexing) is easily achieved by introducing several sgRNAs. The simplicity of sgRNA production has made it possible to generate libraries of knockout guide RNAs for either human or mouse genes that are useful for forward genetic screens (Koike-Yusa et al., 2013; Shalem et al., 2014).

DNA Double-Strand Break Repair in Neurons
DNA double-strand breaks (DSBs) induced by targetable endonucleases are only the first step in mutagenesis (Figure 1B). The perturbation of the genomic DNA sequence is useful in genome engineering only because cellular DNA damage signals and repair machineries are activated and fix the damaged sequence. It is the repair process that we exploit to isolate desired disease alleles or to revert mutations to wild-type sequences.

Such DNA repair pathways are rapidly mobilized after damage because maintaining genomic integrity is critical for cell survival and function. DNA damage can occur in many ways. Cell metabolism generates oxidative DNA damage, ultraviolet radiation results in single- or double-strand breaks, and cross-linking agents lead to intra- or inter-strand linkages (Lindahl, 1993; Rao, 1993; Brooks, 2002; Caldecott, 2008; McKinnon, 2013; Pan et al., 2014). Among the many forms of DNA damage, double-strand breaks (DSBs) are considered the most detrimental and are repaired by three major pathways: homologous recombination (HR), homology-directed repair (HDR), and non-homologous end joining (NHEJ) (Figure 1B; Lieber, 2010; Chiruvella et al., 2013; Jasin and Rothstein, 2013). The HR pathway allows an error-free repair and requires an extensive sequence homology from which the sequences of the damaged DNA can be faithfully copied. The sequence homology is provided by the sister chromatid, and thus HR is operational during the S and early G2 phases of the cell cycle during which the sister chromatid is available (Potter et al., 1987; Maryon and Carroll, 1991; Benjamin and Little, 1992; Kadyk and Hartwell, 1992). NHEJ is an error-prone process in which the broken DNA ends are directly ligated through the end processing proteins, Ku70/Ku80 [a part of DNA dependent protein kinase (DNA-PK)], catalytic subunit of DNA-PK (DNA-PKcs), and ligase IV (Critchlow and Jackson, 1998). During this end-joining process, small-scale nucleotide insertions and deletions (indels) are commonly involved (Heidenreich et al., 2003). Since NHEJ does not require a homology sequence, it can occur throughout the cell cycle. HDR broadly defines a wide array of homology-dependent pathways of the DNA repair including single-strand annealing (SSA) and alternative NHEJ, also called microhomology-mediated end joining (MMEJ; He et al., 2015). MMEJ utilizes small homologous sequences (1–25 nt) within either end of the broken DNA (Liang et al., 2008; McVey and Lee, 2008). Like NHEJ, most HDR processes can occur throughout the cell cycle. On the basis that both HDR and HR use homologous sequences, HR can be considered part of HDR (Lieber, 2010). Yet, HR possesses processes unfound in HDR or NHEJ, such as extensive processing of the 5′-end of the DNA lesion and strand invasion by the Rad51-bound 3′-end of the lesion (Maryon and Carroll, 1991; Shinohara et al., 1992; Van Dyck et al., 1999; Jasin and Rothstein, 2013). Since DNA repair is a critical process for cell survival, the various repair pathways can be activated by different damage signals. Although there are proteins dedicated to a particular pathway, many of the signaling and repair molecules are redundant rather than exclusive to a single pathway (Takata et al., 1998; Madabhushi et al., 2014). DNA repair pathways are utilized in two distinct phases in neurons. During the development of an organism, the highly proliferative neural tissues mainly use HR. At this stage, failure to faithfully repair the genome leads to apoptosis (Waser et al., 1979; Sugo et al., 2000; Orii et al., 2006). Since a single error in
progenitor cells can lead to severe failures in a large number of cells, either a complete repair or abortive apoptosis is adaptive for the survival of the organism. Once neurons develop, the mature neurons are post-mitotic and their DNA is no longer replicated. In these mature neurons, the sister chromatid with sequence homology is not available and therefore HR is rare. NHEJ is considered to be the major pathway for DNA repair in adult neurons and apoptosis is not promoted (Sonoda et al., 2006; Fortini and Dogliotti, 2010; Iyama and Wilson, 2013). Whereas global repair activities are down-regulated in post-mitotic neurons, transcription-dependent DNA repair pathways are highly active, and transcribed genes are actively repaired regardless of the type of DNA damage (e.g., single strand or double-strand breaks; Nouspikel and Hanawalt, 2000, 2002). Although there is mounting evidence that connects DNA DSBs to neurodegeneration (Hochegger et al., 2006; Wang et al., 2013; Rulten et al., 2014), it is still not clear how these DSBs lead to neurodegeneration in mature neurons (for a review, see McKinnon, 2013; Madabhushi et al., 2014). Also uncertain is whether it is the type or number of errors that contributes to neurodegeneration.

Recently, it was found that DNA DSBs occur as part of normal neuronal physiology, and these DSBs are closely tied to learning, memory, and novel experience-dependent synaptic changes (Suberbielle et al., 2013; Madabhushi et al., 2015). These DSBs have been demonstrated to be required in the promoter regions of early-response genes—responsible for memory formation and synaptic consolidations—in primary neuron culture and hippocampal slices of Swiss Webster mice, and also in an in vivo training paradigm for contextual fear conditioning in 6-month-old mice (Madabhushi et al., 2015). In an exploration of novel environment learning paradigm, the DSBs in hippocampal regions in 4-7-month-old mice are repaired within 24 h of the occurrence (Suberbielle et al., 2013). The pathogenic protein in Alzheimer’s disease, amyloid-beta, made DSBs persist beyond the 24-h period in 4-7-month-old human amyloid precursor protein (hAPP) transgenic mice (Suberbielle et al., 2013). In addition, DSB repair protein BRCA1 is depleted in a mouse model of Alzheimer’s disease, and the depletion is correlated with cognitive decline in mice compared to wild-type mice (Suberbielle et al., 2015). These findings indicate that functional DSB repair is associated with normal neuronal physiology and impaired DSB repair with pathophysiology.

The distinctive DNA repair mechanisms and physiologic utility of DSBs in neurons warrant further investigation on the consequences of using targetable endonucleases in the nervous system. The majority of studies on the functions of PDBAs and the outcomes of PDBA applications were conducted with dividing cell lines such as immortalized cells (Cermak et al., 2011; Christian et al., 2012; Garg et al., 2012; Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013) or stem cells (Hockemeyer et al., 2011; Cong et al., 2013; Ding et al., 2013a,b; Osborn et al., 2013; Mali et al., 2013b). The result of PDBA-induced DSBs is likely to be different in post-mitotic neurons compared with mitotic cells. For example, a faithful sequence correction might be more difficult in nervous tissues since the incorporation of exogenous DNA might be favorably mediated by HDR or NHEJ, both of which are more error-prone repair processes than HR. Or, it could be that neurons might activate the HR pathway if given exogenous DNA templates. These questions need to be empirically determined. Once detrimental mutations occur by DSBs, the nervous tissue would be more susceptible to degeneration since the restoration of the cell population through cell divisions is unlikely. These considerations need to be taken into account when targeting PDBAs in the nervous system as somatic therapeutic agents. Developing an experimental system with which nervous tissue-specific perturbations can be tested will be invaluable to spur therapeutic PDBA development targeting neuronal disorders.

**NHEJ: Knock-Outs**

Since indels in the NHEJ pathway can lead to frameshift mutations producing dysfunctional truncated proteins and loss of protein, NHEJ has been the predominant mode of PDBA-mediated mutagenesis. In earlier applications of PDBA-mediated targeted NHEJ in neuroscience, neuronal genes are targeted in dividing cells to demonstrate that mutations can be introduced at the target loci. Cong et al. targeted EMX1, Th, and PVAlB implicated in neurodevelopment or neurodegeneration using a Cas9 system in HEK293FT cells (Cong et al., 2013; Table 1). PDBA-mediated NHEJ enabled an important advance in rapid modeling of human diseases in animals and cell lines. With PDBAs, virtually any genetic make-up with a well-defined genetic basis (e.g., monogenic) can be produced to model a disease in terms of genomic sequences, if we set aside for another discussion the caveats of biologically replicating the phenotypes, genetic compensation in germline mutants, and embryonic lethality in essential genes. Several investigations have introduced mutations to neuronal loci in zebrafish using ZFNs (Schmid et al., 2013), TALENs (Bedell et al., 2012; Huang et al., 2013), and a Cas9 system (Hwang et al., 2013), in rats using TALENs (Ferguson et al., 2013), and in mice and rats using a Cas9 system (Li et al., 2013; Tables 1, 2). PDBA-mediated NHEJ has made it possible to model neuropsychological and neurodevelopmental disorders in animals that were previously not possible due to lack of germline competent embryonic stem cells (ESCs). Using TALENs, two groups reported successful modification of the MECP2 locus implicated in Rett syndrome in non-human primate models (Liu H. et al., 2014; Liu Z. et al., 2014). In these two investigations, only one group saw successful birth of injected animals (Liu H. et al., 2014). The fact that the other group could not maintain the surrogate mother’s pregnancy of injected zygotes indicates that mosaic P0 animals might not be viable when the mutagenic efficiency of PDBAs is high. Another group targeted PPARG—implicated in neurodegeneration—with a Cas9 system in cynomolgus monkeys (Macaca fascicularis; Niu et al., 2014). These genetic perturbations have not been fully investigated yet for their phenotypes, nor the degree to which they model human diseases. More follow-up investigations are expected in which the biological relevance of the models to human diseases is reported.

Moving beyond dividing cells and germline mutations in mutant animals, four groups directly applied Cas9 systems in post-mitotic neurons in which two synaptic proteins, an NMDA receptor subunit (Incontro et al., 2014; Straub et al., 2014) and
## TABLE 1 | Neuronal target loci: knock-out.

| References           | Locus* | Implication** | System                      | Delivery                                | Goal                        | Perturbation | Results                        |
|----------------------|--------|---------------|-----------------------------|-----------------------------------------|-----------------------------|--------------|--------------------------------|
| Keatinge et al., 2015| gba1   | GD, PD        | Zebrafish                   | 1-cell embryo injection of TALEN mRNA  | Germine transmission       | KO; small indels | gba1: c.1276_1298del mutant line |
| Yao et al., 2015     | Gpr52  | HD            | Mouse                       | Zygote injection of TALEN mRNA         | Germine transmission       | KO; small indels | Indel mutants                  |
| Mehrabian et al., 2014 | Pnp   | Prion diseases, AD | N2a, C2C12, NMuMG cells    | Cas9 and sgRNA plasmid co-transfection | Mutant cell lines         | KO; small indels | Indel mutant lines             |
| Zuris et al., 2014   | EMX1; Tau-EGFP | Neuronal marker | HEK293ST; mESCs            | Cationic lipid transfection of Cas9:sgRNA protein:RNA complex | Mutant cell lines         | KO; small indels | Loss of mutations; Loss of GFP signal |
|                      |        |               | Mouse, adult                | Cocclear injection of cationic lipid prep of Cas9:sgRNA protein:RNA complex | Somatic and local alteration of genomic sequence | KO; small indels | Loss of GFP signal; Indel mutations |
| Swiech et al., 2014  | Mecp2  | Rett syndrome | Mouse primary cortical neurons (E18) | AAV-Cas9 and AAV-sgRNA vector co-transduction | Mutant primary cells       | KO; small indels | Indel mutant cells             |
|                      |        |               | Mouse, adult                | Hipp DG injection of AAV-Cas9 and AAV-sgRNA vectors | Somatic and local alteration of genomic sequence | KO; small indels | Indel mutations                  |
|                     | Dnmt1, Dnmt3a, Dnmt3b | Synaptic plasticity | Mouse, adult | Hipp DG injection of AAV-Cas9 and AAV-sgRNA vectors; multiplexing | Somatic and local alteration of genomic sequence | KO; small indels | Indel mutations |
| Incontro et al., 2014| Grin1, Gria2 | Synaptic plasticity and transmission | Hipp slice or dissociated culture of postnatal rat | Biolistic co-transfection of Cas9 and sgRNA plasmids or lentiviral vector co-transduction | Mutant primary cells | KO; small indels | Indel mutant cells |
| Straub et al., 2014  | Grin1  | Synaptic plasticity | Mouse | Intratrauterine electroporation of Cas9, sgRNA, and GFP plasmids | Somatic and local alteration of genomic sequence, | – | Functional analysis of KO through electrophysiology |
|                      |        |               | hipp slice culture of postnatal rat | Biolistic transfection (rat) of Cas9, sgRNA, GFP plasmids | Mutant primary cells | – | Functional analysis of KO through electrophysiology |
| Ponomareva et al., 2014 | clstn-1 | Axon branching, endosomal trafficking, AD | Zebrafish | 1-cell embryo injection of TALEN mRNA | Germine transmission       | KO; small indels | clstn-1 mutant line |
| Liu H. et al., 2014  | MECP2  | Rett syndrome | Rhesus and cynomolgus monkeys | Zygote injection of TALEN plasmids | Germine transmission       | KO; small indels; SNPs | F0 mosaic mutants obtained |
| Richard et al., 2014 | Artifical trinucleotide repeats | Neurodegeneration | Yeast | TALEN plasmid transformation in yeast strains | Yeast cells with sequence alterations | KO; deletions | Trinucleotide contraction |
| Liu Z. et al., 2014  | MECP2  | Rett syndrome | Cynomolgus monkeys | Zygote injection of TALEN mRNA | Germine transmission       | KO; small indels | A F0 mosaic mutant stillborn |

(Continued)
an AMPA receptor subunit (Incontro et al., 2014), are targeted (Table 1). Straub et al. locally altered the genomic sequence in a Grin1 locus (NMDA receptor subunit 1) in vivo in E15 mouse hippocampi by delivering Cas9 and sgRNA plasmids through in-uterro electroporation, as well as in hippocampal slice culture through biolistic transfection (Straub et al., 2014). The resulting neurons showed altered electrophysiological profiles providing functional evidence that the target gene, Grin1, is knocked down. However, mutations were not directly sequenced. Incontro et al. knocked out either Grin1 or Gria2 (AMPA subunit 2) in hippocampal slice culture from 6 to 11-day-old rats by delivering Cas9 and sgRNA plasmids through biolistic transfection (14-day expression of the construct before electrophysiology; Incontro et al., 2014). Incontro et al. showed that electrophysiological profiles were altered in the knock-out cells. They also reported that >90% of the mutations in Grin1 had indel mutations that were out-of-frame and that the function of the target protein was impaired. Similarly, Swiech et al. targeted Mecp2 or DNA methyltransferases (Dnmt1, Dnmt3a, and Dnmt3b; via multiplexing) in post-mitotic neurons in vitro and in vivo.
TABLE 2 | Neuronal target loci: knock-in.

| References         | Locus* | Implication** | System                                      | Delivery                                      | Goal or mutant cell lines | Perturbation                          | Results                                      |
|--------------------|--------|---------------|---------------------------------------------|-----------------------------------------------|---------------------------|----------------------------------------|---------------------------------------------|
| Wen et al., 2016   | DISC1  | Schizophrenia | iPSCs, forebrain neurons                    | TALEN and donor plasmid co-transfection in iPSCs | WT or mutant cell lines   | Ki; correction or introduction of patient mutation | DISC1WT or DISC1Δbp-del                  |
| Lenzi et al., 2015 | FUS    | ALS           | iPSCs, spinal motoneurons                   | TALEN and donor plasmid co-transfection       | Mutant cell lines         | Ki; codon replacement                  | FUSPS27SL mutant iPSCs and neurons         |
| Vannocci et al., 2015 | FXN  | Friedreich’s ataxia | HEK293                                     | Donor and TALEN or Cas9/sgRNA plasmid co-transfection | Mutant cell lines         | Ki; Introduction of donor sequence     | Inducible FXN mutants                     |
| Kiskinis et al., 2014 | SOD1 | ALS           | iPSCs, spinal motoneurons                   | ZFN and donor plasmid co-transfection in iPSCs | Mutant cell lines         | Ki; correction of patient mutation     | SOD1A4V → SOD1WT                         |
| Wainger et al., 2014 | SOD1 | ALS           | Same method as Kiskinis et al., 2014        | –                                              | –                          | –                                      | –                                          |
| Chen et al., 2014   | SOD1  | ALS           | iPSCs, spinal motoneurons                   | TALEN and donor plasmid co-transfection in iPSCs | Mutant cell lines         | Ki; correction of patient mutation     | SOD1D90A → SOD1WT                       |
| Sanders et al., 2014 | LRRK2| PD            | iPSCs, dopaminergic neurons                 | ZFN and donor co-transfection in iPSCs        | WT cell line              | Ki; correction of patient mutation     | LRRK2G2019S → LRRK2G2019S                 |
| An et al., 2014     | HTT    | HD            | HEK293, iPSCs                               | Cas9 WT, Cas9 nickase, or TALEN and donor plasmid co-transfection | Mutant cell lines         | Ki; introduction of mutation           | HTT^97Q                                   |
| Jones and Meisler, 2014 | Scn8a | Epileptic encephalopathy | Mouse                                     | Zygote injection of TALEN mRNA and donor plasmid | Germline transmission    | Ki; introduction of mutation           | Scn8a^1768D mutant                       |
| Hruscha et al., 2013 | tardbp, tardbp, C13H9orf72 | ALS, FTD | Zebrfish                                   | 1-cell embryo injection of Cas9 mRNA and sgRNA | Germline transmission    | KO; small indels                        | Indel mutants                            |
| Panda et al., 2013  | FUS    | ALS           | Mouse                                      | Zygote injection to pronuclei of TALEN mRNA and ssODNs | Germline transmission    | Ki; codon replacement                  | FUS^513G or FUS^517L mutant               |
| Zu et al., 2013     | th     | Dystonia      | Zebrfish                                   | 1-cell embryo injection of TALEN mRNA and donor plasmids | Germline transmission    | KO; small indels                        | Indel mutants                            |
| Fong et al., 2013   | MAPT   | Tauopathy     | iPSCs, dopaminergic, glutamatergic, or GABAergic neurons | ZFN and donor plasmid co-transfection in iPSCs | Mutant cell lines         | Ki; correction or introduction of patient mutation | MAPT^1527/1527 or MAPT^WT/WT             |
| Frontiers in Genetics | www.frontiersin.org | | | | | | |
by stereotactically delivering Cas9 and sgRNA in adeno-associated viral vectors to the hippocampal dentate gyrus in adult mice (Swiech et al., 2014; Table 1). In primary cortical neuron culture, ~70% of transduced cells showed knock-out of Mecp2 by immunocytochemistry, western blot, and next generation sequencing. The in vivo knock-out efficiency was ~68% in purified nuclei of transduced cells (in vivo transduction efficiency of the vector was ~80%) from dissected brain tissue. The Mecp2 mutations led to altered performance in a contextual fear-conditioning paradigm, reinforcing that the in vivo knockdown of Mecp2 in hippocampal cells has neuronal and behavioral consequences. Swiech et al. also demonstrated that somatic Mecp2 knockdown affects the functions of neural circuits by showing altered primary visual cortex (V1) function when Mecp2 was targeted in the superficial layers of V1. Multiplexed targeting in vivo created mutations in Dnmt3a, Dnmt1, and Dnmt3b loci with ~75, ~75, and ~50% indel rates, respectively, when the three loci were targeted in a single transduction in the hippocampus (Incontro et al., 2014). Swiech et al. demonstrated that Cas9-mediated multiplexed gene targeting in the nervous system can be accomplished in vitro, in vivo, and in localized somatic application as well as through zygotic injections. Most recently, Zuris et al. demonstrated non-viral delivery of PDBAs in in vitro and in vivo post-mitotic neuronal cells (Zuris et al., 2014; Table 1). Zuris et al. delivered a Cas9:sgRNA protein:RNA complex in cationic lipid to the cochlear and altered the EMX1 locus with ~20% efficiency in neuronal cells (the outer hair cell) in 1-day-old mice. These four cases represent diverse Cas9 systems delivered with DNA plasmids, viral vectors, or cationic lipids, which are directly applicable to post-mitotic neurons in vitro and in vivo. These work demonstrate the feasibility of neuronal genome engineering and provide evidence that the mutagenic efficiency is comparable to or higher than that in dividing cells.

In addition to neuronal applications of PDBA-mediated NHEJ, understanding and exploiting the properties of NHEJ are underway in many investigations. Beyond out-of-frame knockouts, in-frame indel mutations also occur and may be useful to study the function of specific amino acid residues or putative protein domains (Sung et al., 2013). Microhomology-mediated end joining (MMEJ) often results in deletions or translocations (He et al., 2015). First shown in mammalian cells in 1986, MMEJ has become a useful tool to bias deletions toward frameshift mutations (Roth and Wilson, 1986). The property of MMEJ that allows researchers to better predict mutagenic outcomes might be particularly useful for neuroscientists since NHEJ—resulting in random mutations—appears to be more active compared to dividing cells. Several software options provide microhomology-based prediction functions to design TALENs and CRISPR/Cas9 gRNAs that are more likely to induce frameshift mutations (Neff et al., 2013; Bae et al., 2014a).

### HDR and HR: Knock-Ins

Unlike the NHEJ repair pathway, HR and some versions of HDR utilize an external DNA donor and repair the DNA damage without introducing erroneous sequences. A single-stranded oligo with short sequence homology (~50 nt) to the genomic DNA can act as a template for HDR, and a donor DNA construct with extended homology arms (hundreds to thousands of bps) can act as a template in HR. Applications of PDBA-mediated knock-ins in neuroscience have focused on engineering induced pluripotent stem cells (iPSCs) and generating animal models (Table 2). First, it has been a widely-used and effective approach to engineer patient-derived iPSCs with PDBAs to revert a disease-causing allele to wild-type via HDR and to differentiate these engineered and control (without modification) iPSCs to neurons. The genome engineered iPSCs and neurons

---

**Table 2** | Continued

| References          | Locus* | Implication** | System | Delivery       | Goal                  | Perturbation          | Results                  |
|---------------------|--------|---------------|--------|----------------|------------------------|------------------------|--------------------------|
| Bedell et al., 2012 | crhr1   | HPA axis modulation, anxiety | Zebrafish | 1-cell embryo injection of TALEN mRNA | Germline transmission | KO; small indels | Indel mutants |
| crhr2               | Eating disorder |              |        | 1-cell embryo injection of TALEN mRNA and ssODN | Germline transmission | Ki; introduction of LoxP sequence | Mutants                  |
| Soldner et al., 2011| SNCA   | PD            | hESCs, iPSCs | ZFN and donor plasmid co-transfection | Mutant or WT cell lines | Ki; introduction or correction of patient mutation | SNCA**STOP, SNCA**E46K, mutant, SNCA**WT |

Programmable DNA-binding agents (PDBAs; ZF, TALE, and Cas systems) are applied to knock-in exogenous sequences at target loci.

*Loci: 310043021Rk, mouse homolog of the human C9orf72; C9orf72, chromosome 9 open reading frame 72; C13R9orf72, zebrafish homolog of the human C9orf72; DISC1, disrupted in schizophrenia 1; FUS, fused in sarcoma/translocated in liposarcoma; FXN, frataxin; HTT, huntingtin; MAPT, microtubule-associated protein Tau; MECP2, methyl-CpG binding protein 2 gene; PPARG, peroxisome proliferator-activated receptor gamma; SOD1, superoxide dismutase 1; TDP-43, transactive response DNA binding protein 43 kDa (TDP-43); SNCA, alpha-synuclein, non A4 component of amyloid precursor; TARDBP, transactive response DNA binding protein 43 kDa (TDP-43), zebrafish homolog of TDP-43; SNCA, alpha-synuclein, non A4 component of amyloid precursor; SOD1, superoxide dismutase 1; tardbp, transactive response DNA binding protein 43 kDa (TDP-43), zebrafish homolog of TDP-43; tbrbp, transactive response DNA binding protein 43 kDa (TDP-43), zebrafish homolog of TDP-43; thr, tyrosine hydroxylase, zebrafish homolog of human THR.

**Implication:** AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; glia, neoplasms in the central nervous system; HD, Huntington’s disease; PD, Parkinson’s disease.

Cas, CRISPR-associated; ESCs, embryonic stem cells; F0, PDBA-injected generation; hESCs, human ESCs; HSV, herpes simplex virus; herpes simplex viral vector; inducible, insertion and deletion mutations; iPSCs, induced pluripotent stem cells; KI, knock-in; KO, knock-out; sgRNA, single guide RNA; ssODNs, single stranded oligodeoxyribonucleotides; TALENs, transcription activator-like effector nucleases; ZF, zinc finger; ZFN, zinc finger nuclease.
are identical to the patients’ cells except the corrected DNA sequences and a certain level of single nucleotide polymorphisms (SNPs) inherent to all stem cell models. Patient-derived iPSCs have been used to investigate altered cellular functions and establish cell-autonomous disease models in Parkinson’s disease (PD), tauopathy, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Huntington’s disease (HD) using ZFN (Soldner et al., 2011; Fong et al., 2013; Kiskinis et al., 2014; Sanders et al., 2014), TALEN (Woodruff et al., 2013; Chen et al., 2014; Lenzi et al., 2015; Wen et al., 2016), and Cas9 systems (An et al., 2014; Table 2).

Whereas a knock-in approach had been challenging and time-consuming in animal models, PDBAs have spurred the generation of knock-in cell and animal models based on increased efficiencies of HR. When considering the rates of classic HR to be $\sim 1 \times 10^{-3}$ and $1 \times 10^{-6}$ (Smithies et al., 1985; Thomas and Capecchi, 1986; Puchta et al., 1993; Rouet et al., 1994; Choulika et al., 1995; Rong and Golic, 2001), PDBAs can increase donor sequence integration at a rate of $\sim 1-45\%$ by generating DSBs in the genomic target locus (Urnov et al., 2005; Beumer et al., 2008; Greenwald et al., 2010; Li et al., 2013; Zu et al., 2013; Gratz et al., 2014; Krentz et al., 2014; Platt et al., 2014; Shin et al., 2014a; Xie F. et al., 2014a; Karakikes et al., 2015; Lee et al., 2015; Wang et al., 2016). Although direct comparison is nearly impossible because of the differences in the knock-in system, including the size and design of the donor, selection systems, and target loci in the genome, targeted DSBs with PDBAs are viewed as improving HR rates by 3–6 orders of magnitude. Bedell et al. first showed in vivo knock-in of modified LoxP sequences in a neuronal locus, crhr2, by zygote injection of TALEN mRNA and a single-stranded oligonucleotide in zebrafish (Bedell et al., 2012; Table 2). Currently, patient allelic variants of many neuronal disorders have been introduced and modeled in mice and zebrafish using TALEN (Panda et al., 2013; Jones and Meisler, 2014) and Cas9 systems (Hruscha et al., 2013) ranging from epilepsy to schizophrenia (Table 2).

Directly knocking-in exogenous DNA sequences with PDBAs in post-mitotic neurons has not been reported to our knowledge. It will be an important area of investigation when developing therapeutics, and the mechanism of foreign DNA knock-in is being pursued to improve future therapeutic applications. It is important to recognize that the NHEJ, HDR, or HR pathways all can be used to introduce exogenous DNA sequences into the genome. A linear piece of double-stranded DNA may be incorporated into the genome even during NHEJ repair (Lin and Waldman, 2001; Miller et al., 2004; Gabriel et al., 2011). This NHEJ process is still prone to errors at the break site and the mechanism is unclear. Inactivating key components of the NHEJ pathway (e.g., ligase IV) has been demonstrated to bias DSB repair away from NHEJ, in one example increasing HR efficiency by 20–65% in Drosophila (Beumer et al., 2008). Another way to circumvent the NHEJ pathway is by generating single-strand overhangs with nickases and providing a double-stranded oligo with complementary overhangs on either side (Ran et al., 2013). Albeit with lower efficiency, HR-based knock-ins with short or long homology arms allow many experimental manipulations—including the introduction of promoters, reporters, recombination sites, and wild-type alleles—with high accuracy and are utilized in neuroscience research (Liu et al., 2011; Corti et al., 2012).

### EPIGENETIC MODIFICATION AND TRANSCRIPTIONAL CONTROL

There are estimated to be hundreds to thousands of types of neuronal cell populations (Stevens, 1998; Shin et al., 2014b) in the mammalian cortex, suggesting equally complex epigenetics in the nervous system. Development, physiological function (such as memory consolidation), and pathological changes in neuropsychiatric and neurodegenerative disorders are closely tied to epigenetic changes (for a review, see Tsankova et al., 2007; Morris and Monteggia, 2014; Reul, 2014). In recent years, we have significantly broadened our understanding of the three-dimensional structures and organizations of chromatin in the nucleus (Takizawa and Mesher, 2008; Lieberman-Aiden et al., 2009; Phillips-Cremins et al., 2013; Rao et al., 2014). Similar to how the deluge of genomic sequencing data has urged the functional study of disease-associated and candidate genes, we are in need of functional understanding of higher chromatin structures and their connection to neuronal diseases. The ability to perturb epigenetic states, gene expression patterns, and higher order chromatin structures in a targeted manner has been largely unavailable. Although it is still at a fledging state, we will discuss multiple investigations that have reported success in direct modulation of gene expression, epigenetic modulation, building synthetic circuits, and modifying regulatory elements in mammalian cells, yeasts, and prokaryotes using PDBAs. The majority of the studies were conducted in dividing cells, and only a small portion of the studies targeted neuronal loci. Still, these early studies demonstrate the feasibility of controlling regulatory elements with PDBAs and are worth a discussion for their future adoption in the nervous system.

#### Regulation of Gene Expression

As the name implies, TALEs were first identified and adapted as transcription factors (Bai et al., 2000; Gu et al., 2005; Boch et al., 2009; Moscou and Bogdanove, 2009). Applying this inherent functionality, TALEs have been used to up-regulate the expression of specific genes at targeted loci (Zhang et al., 2011; Figure 2A). The application of single TALEs showed a moderate effect of two to five-fold increases in target gene expression in endogenous loci (SOX2, KLF4) in HEK293T cells, but the fold increase could be augmented from 50- to 10,000-fold by applying multiple TALEs targeting an endogenous promoter (Perez-Pinera et al., 2013b; Maeder et al., 2013c). Replacing the TALE’s native activation domain with a stronger activation domain (VP16 and later VP64) increased activation by 10 times in a reporter system (Geißler et al., 2011). In addition, TALEs have been shown to repress gene expression when fused to a repressor domain such as the EAR-repression domain (SRDX) in plants (Mahfouz et al., 2011) and the Krüppel-associated box (KRAB) or Mad interaction domain (SID) in human cells (Cong et al., 2013).
2012). Yet, the modulatory effects of TALEs are inconsistent. Some TALEs show a higher activity while some fail to modulate the transcription of the target locus. Although this ineffectiveness was attributed to repressed regions of chromatin (Zhang et al., 2011; Bultmann et al., 2012), other studies showed that TALEs can activate transcription even in repressed chromatin regions (Scott et al., 2014b). One explanation for this discrepancy is the location of the TALE binding site in relation to nucleosome binding. In particular, the activity of TALEs was higher when targeting DNA sequences that are accessible in the nucleosome, while not as efficient when targeted to sites covered by the dyad of the nucleosomes (Scott et al., 2014a). Three studies using TALENs reported modulation of gene expression in neuronal loci (Table 3). Cong et al. showed ∼5- and three-fold up-regulation of mRNA in CACNA1C target loci 1 and 2 with TALE-VP64 in HEK293FT cells (Cong et al., 2012). Targeting NTF3 in HEK293 cells, Miller et al. reported a ∼30-fold increase in mRNA expression with TALE-VP16 (Miller et al., 2011) whereas Maeder et al. saw only a modest increase in the same gene with TALE-VP64 (though significant; Maeder et al., 2013c). These two cases show that, even in the same locus, the efficacy of TALE-mediated gene expression may be affected by multiple variables such as target loci, design and concentrations of TALE constructs, cell types, delivery methods, and the genetic make-up of transfected cells or injected animals. Similarly, different types of neurons in varying animal models could respond differently to the application of TALEs.

Although it is useful to be able to modulate gene expression levels at target loci by simply introducing TALEs to the system, these applications act constitutively and lack spatiotemporal control. Inducible TALEs and TALEs with regulated expression systems were developed to provide further spatiotemporal control. Allowing for increased temporal regulation, TALEs bound to a ligand-binding domain could modulate gene expression in response to light (Konermann et al., 2013), endogenous signals (Li et al., 2012), or exogenous ligands (Mercer et al., 2014). The study by Konermann et al. is noteworthy since the authors not only modulated two neuronal targets in an inducible system in dividing cells, primary neuron culture, and in vivo, but also profiled a total of 28 TALE-VP64 systems in primary neuron culture, each of which individually targeted one locus (Konermann et al., 2013). Konermann et al. built a two-hybrid system that allows TALE-mediated gene activation only when blue light (466 nm) is applied. One component of the two-hybrid is a TALE monomer bound to cryptochrome 2 protein (CRY2) effector domain that is sensitive to light and the other comprises a CRY2’s interacting partner (C1B1 protein), nuclear localization signal, and VP64. With light stimulation, Neurog2 mRNA is significantly increased from 30 min onward until about 3 h after stopping the stimulation in N2a cells (mouse neuroblastoma cell line), reaching a peak induction of 20-fold compared to that of unstimulated cells. After AAV-mediated delivery of inducible constructs targeting a Grm2 locus in mouse primary cortical neurons and mice, Konermann et al. observed ∼four- to six-fold increase in Grm2 mRNA after light stimulation in neuronal culture and ∼3.5-fold increase in vivo (Table 3). In a light-inducible repressor system, Konermann et al. fused CRY2 with mSin3 interacting domains that repress gene expression through histone deacetylation and observed two-fold reduction in Grm2 mRNA expression in primary neuron culture (Konermann et al., 2013). Non-inducible TALE-VP64 constructs were tested in neurons as well by individually targeting 28 neuronal loci with a significant fold increase ranging from ∼1.5 (Grin2a) to ~33 (Slc6a4).

To generate controlled and coordinated gene circuits, TALEs that interact with regulatory elements were developed, including TALEs that control synthetic promoters or TALEs that are expressed under the control of an artificial regulatory element. Multiple synthetic promoters that contain a TALE-binding site simultaneously activated gene expression in multiple loci in
## TABLE 3 | Neuronal target loci: gene expression.

| References | Locus* | Implication** | System | Delivery | Goal | Perturbation | Results |
|------------|--------|---------------|--------|----------|------|--------------|---------|
| Amin et al., 2015 | miR-218-1; miR-218-2*** | Motoneuron disease | Mouse | Zygote injection of Cas9 mRNA and two sgRNAs | Germline transmission | KO; deletion | miR-218-1/290bp-del or miR-218-2/290bp-del mutant |
| Zuris et al., 2014 | NTF3 | Neurode generation | HEK293T | Cationic lipid transfection of (-30)GFP-TALE-VP64 protein or dCas9-VP64:sgRNA protein:RNA complex | Transient alteration of gene expression | – | Increased gene expression |
| Heller et al., 2014 | Fosb | Addiction, depression | Mouse (juvenile 7–8 wks old) | HSV transduction of ZF+effector (p65 or G9a) plasmids | Transient and local alteration of gene expression | Acetylation or methylation of promoter | Up or down-regulation of gene expression |
| Konermann et al., 2013 | Neurog2, Gmr2 + 27 other neuronal genes | Neural differentiation, PD, Schizophrenia | N2a, mouse primary cortical neurons, mouse | Transfection of light-inducible TALE plasmids; transduction of light inducible AAV-TALE vectors | Light-induced transient alteration of gene expression | – | Increased gene expression with an improved temporal control |
| Maeder et al., 2013b | NTF3 | Neurode generation | HEK293 | dCas9-VP64 and sgRNA plasmid co-transfection | Transient alteration of gene expression | – | Increased gene expression |
| Chapdelaine et al., 2013 | PN1 | Friedreich’s ataxia | Human and mouse fibroblast | TALE-VP64 plasmid transfection | Transient alteration of gene expression | – | Increased gene expression |
| Maeder et al., 2013c | NTF3 | Neurode generation | HEK293 | TALE-VP64 or TALE-p65 plasmid transfection | Transient alteration of gene expression | – | Increased gene expression |
| Garriga-Canut et al., 2012 | HTT | HD | STHdh cells, mouse | ZFP plasmid or AAV2/1 vector transfection; | Transient or stable alteration of gene expression | – | Decreased gene expression |
| Cong et al., 2012 | CACNA1C | Autism | HEK293FT | TALE-VP64 plasmid transfection | Transient alteration of gene expression | – | Increased gene expression |
| Miller et al., 2011 | NTF3 | Neurode generation | HEK293 | TALE-VP64 plasmid transfection | Transient alteration of gene expression | – | Increased gene expression |
| Laganiere et al., 2010 | GDNF | PD | Human, monkey, and rat cells | Lentiviral transduction of ZF-p65 | Alteration of gene expression | – | Increased gene expression |

Programmable DNA-binding agents (PDBAs; ZF, TALE, and RAN-guided Cas systems) are applied to modulate target gene expression.

* Loci: CACNA1C, calcium channel voltage-dependent L-type alpha 1C subunit; Gdnf, glial cell line-derived neurotrophic factor, rat homolog of human GDNF; Gmr2, glutamate receptor metabotropic 2, mouse homolog of human GRM2; HTT, huntingtin; miR-218-1, miR-218-2, microRNA-218 mammalian paralog 1, 2; Neurog2, neurogenin 2, mouse homolog of human NEUROG2; NTF3, neurotrophin 3.

** Implication: HD, Huntington’s disease; PD, Parkinson’s disease.

*** miR-218 and miR-218-2 are knocked out through deletion (370 bp, 290 bp). This study by Amin et al. is included in gene expression modulation section because the indels in the regulatory elements mainly concern gene expression patterns. (-30)GFP-TALE-VP64, engineered GFP protein with electrostatic charge of -30 fused to TALE-VP64; AAV2, adeno-associated virus type 2; Cas, CRISPR-associated; dCas, dead Cas; enzymatically inactive; G9a, histone methyltransferase, encoded by EHMT2, euchromatic histone-lysine N-methyltransferase 2; HA tag, human influenza hemagglutinin amino acids 98–106 epitope tag; HEK293, human embryonic kidney cell derivative line; HSV, herpes simplex virus; herpes simplex viral vector; indels, insertion and deletion mutations; KO, knock-out; N2a, mouse Neuro 2a cell line derived from neuroblastoma; p65, NF-κB activation domain; sgRNA, single guide RNA; STHdh, neuronal progenitor cell line from mouse embryonic day 14 striatal primordial, first exon of the mouse Htt gene has been replaced by a human HTT exon with 111 CAG repeats; TALE, transcription activator-like effector; TALENs, transcription activator-like effector nucleases; VP64, tetrameric repeat of herpes simplex virus activation domain (VP16); ZF, zinc finger; ZFN, zinc finger nuclease.
plants (Brückner et al., 2015), which showed the potential for a coordinated control of multiple genes. A similar system was developed to allow for a temporal regulation of TALE expression and circuit-level control of multiple genes in prokaryotes (Rai et al., 2015). RiboTALEs incorporate riboswitches upstream of the TALE-encoding sequences to regulate the time at which TALEs are expressed. Once expressed, TALEs repress gene expression of target loci that are engineered to have a TALE-binding site (Rai et al., 2015). Improved spatiotemporal control was also demonstrated in mammalian cells by combining the well-established tetracycline-response element (TRE) and Gal4-UAS system with TALEs fused to a repressor domain (Li Y. et al., 2015). Combining a TALE-repressor with other regulatory systems—in this case, TRE and Gal4-UAS—produced a synthetic circuit via a two-hybrid regulatory system.

Similar modulations of gene expression were achieved by engineered CRISPR/Cas systems. Unlike TALEs, the innate function of the CRISPR/Cas system is to make DNA DSBs as a bacterial adaptive immune system in nature (Barrangou et al., 2007; Garneau et al., 2010). To co-opt the CRISPR/Cas system as a transcription factor system, the innate endonuclease function of Cas9 is catalytically inactivated (dCas9; dead Cas9) by introducing D10A and H841A mutations within the nuclease domains, RuvC1 and HNH, respectively (Jinek et al., 2012; Figure 2B). The resulting dCas9 without any fused effector domains tends to block transcription in endogenous loci in prokaryotes and a reporter system in human cells, presumably through steric hindrance to the binding or elongation of the RNA polymerase (RNAP; Qi et al., 2013). dCas9 fused to a repression domain (KRAB) effectively silenced gene expression both in endogenous loci (CD71 and CXCR4) and in a reporter system. When fused to an activating domain (VP64), dCas9 increased GFP expressions in a reporter system (Gilbert et al., 2013). It was not reported if there was an activation in an endogenous locus (Gilbert et al., 2013). A neuronal endogenous locus was targeted with a dCas9-VP64 system showing a moderate (significant) level of increase in NTF3 mRNA (~three-fold) at a concentration of 200 ng sgRNA and 250 ng dCas9-VP64 and a high increase (~5–25) at a concentration of 500 ng sgRNA and 500 ng dCas9-VP64 (Maeder et al., 2013b). This study indicates that applying an optimal concentration without toxicity is an important factor. Robust activation of endogenous gene expression (ranging from 8- to 2000-fold) in human cells (Cheng et al., 2013; Maeder el al., 2013b; Mali et al., 2013a; Perez-Pinera et al., 2013a) and in mouse zygotes (Cheng et al., 2013) was later reported, yet a combination of multiple sgRNAs for each locus was necessary to see effective activation of the target gene in all studies. Mali et al. engineered sgRNA to include MS2 bacteriophage coat protein-binding RNA stem loop at the 3’ end and function as a effector carrying molecule (Mali et al., 2013a). This approach still required multiple sgRNAs to significantly activate an endogenous gene. This is consistent with reports that multiple TALEs function better at increasing the transcription of target locus from two- to five-fold of a single TALE to 50- to 10,000-fold in multiple TALEs. The inability of the CRISPR/dCas9 system to activate gene expression with one sgRNA was recently amended with an alternative approach. Instead of linking effector domains to dCas9, two groups independently engineered the sgRNA secondary structure allowing the binding of effector domains to an sgRNA motif similar to the approach by Mali et al. (Figure 2B). Zalatan et al. incorporated viral RNA sequences of MS2, PP7, and com into sgRNA (this RNA guide is referred to as scaffold RNA; scRNA) that are recognized by the MCP, PCP, and Com RNA-binding proteins, respectively (Zalatan et al., 2015). The MCP, PCP, and Com proteins are fused to an activation (VP64) or repression (KRAB) domain and operate as an RNA-binding adaptor for the effector. This system expanded the two-factor system of sgRNA and dCas9 to a three-factor system of scRNA, dCas9, and adaptor-effector. Utilizing this system, each scRNA activated or repressed a different target locus mediated by different combinations of the adaptor and effector complex, maximizing the orthogonal control of gene regulation (Zalatan et al., 2015). Konermann et al. engineered sgRNA to incorporate dimerized MS2-binding sequences, made an adaptor-effector complex comprising MS2-p65-HSF1, and kept the fused VP64 activation domain on dCas9 (this system is currently referred to as a synergistic activation mediator; SAM; Konermann et al., 2015). Each group showed that one gRNA-mediated targeting could increase gene expression in endogenous loci from ~5-fold (Zalatan et al.) to ~15-fold (Konerman et al.). Zalatan et al. demonstrated orthogonal regulation by simultaneously activating and silencing gene expression, and Konerman et al. introduced an optimized system in activating gene expression.

Besides immortalized human cell lines, the CRISPR/Cas system was tested for gene activation and silencing in prokaryotes (Bikard et al., 2013) and human pluripotent stem cells (hPSCs; Kearns et al., 2013). In Escherichia coli, dCas9, fused to an RNAP omega subunit that stabilizes RNAP at the proximal promoter, increased β-galactosidase activity in a reporter system by ~three-fold (Bikard et al., 2013). In hPSCs, one sgRNA increased endogenous gene expression (SOX17) by 287-fold (Kearns et al., 2013), which was the highest fold increase with one sgRNA in CRISPR/dCas9 applications reported to date in any human cell line or prokaryote. This finding might implicate that distinct regulatory landscapes and mechanisms in different cell lines determine the performance of dCas9 and that CRISPR/dCas9 may be useful to differentiate hPSCs to various types of somatic cells.

Still, when considering effective gene regulation, maximizing the inherent function of each reagent appears to be the best route. In all studies that we have reviewed as of 2015, excepting the report by Kearns et al. TALEs showed a better efficiency in activating endogenous gene expression than did CRISPR/dCas9 in both one and multiple TALE-monomer/sgRNA applications. Gao et al. investigated the efficiency of gene activation between a TALE construct and four different constructs of dCas9 which targeted enhancer regions in Oct4 and Nanog loci (Gao et al., 2014). The report showed that a TALE monomer activated either reporter or endogenous genes significantly better than did any construct of dCas9 with one sgRNA (Gao et al., 2014). Importantly, Gao et al. increased the rigor of the experiment from reporter expression to endogenous gene expression and to cellular reprogramming differentiating mouse embryonic fibroblasts (MEFs) to iPSCs. dCas9s could not
produce any reprogrammed cell colonies even though they could increase the reporter and endogenous gene expression, whereas TALEs produced reprogrammed iPSC colonies (Gao et al., 2014). On the other hand, dCas9 constructs had equivalent or better activity in silencing gene expression than did a TALE monomer (Gao et al., 2014). Gao et al. speculate that the innate steric hindrance that dCas9 shows at the target locus might interfere with the endogenous transcription factor machinery, limiting the capacity of dCas9 to activate gene expression.

Such strengths of dCas9 in silencing gene expression had been shown in an early study in which dCas9 without a repressor domain could override the effect of doxycycline-inducible rtTA (tetracycline transactivator) targeting the same tet operator sequence as the sgRNA (Gilbert et al., 2013). The potent gene repression by dCas9 has been applied to modify the lac regulatory pathway in E. coli (Qi et al., 2013), to reprogram complex biological pathways in yeasts (Zalatan et al., 2015), and to build two-hybrid regulatory circuits with the Gal4 system in mammalian cells (Kiani et al., 2014).

**Modification of Regulatory Elements and Epigenetic Environment**

In addition to the direct regulation of transcription, one can target and modify epigenetic environments and chromatin organizations to investigate important mechanisms of neuronal function. For example, TALEs fused to LSD1 histone demethylase demethylated histones at endogenous enhancer loci and subsequently down-regulated expression of the genes under the control of the targeted enhancer in human cell lines (Mendenhall et al., 2013). In another example, investigations from the Gersbach group using dCas9 fused to an effector domain showed robust modification of histone epigenetic markers. Hilton et al. fused dCas9 to the catalytic domain of human acetyltransferase p300 and observed robust up-regulation of H3K27 acetylation (four- to eight-fold) and of target gene expression (5- to 265-fold; Hilton et al., 2015). Thakore et al. investigated effects of KRAB repressor in epigenetic landscape and found enriched H3K9 trimethylation specifically at the target locus (HS2 enhancer) and consequent gene silencing of multiple globin genes under control of HS2 (Thakore et al., 2015). In addition to histone modifications, the methylation status of DNA contributes to the epigenetic environment. TET1 hydroxylase is responsible for the first step of 5-methylcytosine demethylation, which often activates a promoter (Shin et al., 2014b). This, too, can be modified with PDBAs, and targeted demethylation of CpGs in the promoter by TALEs fused to a TET1 hydroxylase catalytic domain increased the expression in endogenous target loci in human cells (Maeder et al., 2013a).

The genome has higher organizational structures beyond localized epigenetic environments. The multigene complex is one of the higher organizations and represents the locus on the genome where multiple genes on the same or different chromosomes associate with RNA polymerase (RNAP). The transcription of these multiple genes can be synchronously controlled at this multigene complex. Introducing mutations to a multigene complex using TALENs disrupted gene loop formation and significantly decreased gene expression (Fanucchi et al., 2013). Targeting Cas9 with two sgRNAs to the regulatory sequences, Li et al. demonstrated that efficient inversions and duplications of the regulatory elements and gene clusters can be induced in human cells and mice by inducing 2–4 DNA DSBs separated by a few tens of bases to several hundred kilo bases (Li J. et al., 2015). This perturbation was transmitted to offspring and led to the discovery of a new regulatory role of the protocadherin gamma gene cluster.

**VISUALIZATION**

Besides specific manipulation of genomic sequences, PDBAs can be adapted to visualize the native organization of the chromatin. Alterations in DNA structures are implicated in multiple trinucleotide repeat disorders such as Huntington’s disease and spinocerebellar ataxia (Kovtun et al., 2001) as well as hexanucleotide (GGGGCC) repeats in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD; Haeseler et al., 2014). Using new PDBA reagents, genome organization in these disorders may be visualized in live cells. Using TALEs fused to fluorescent proteins (TALE-FP), Ma et al. imaged repetitive DNA sequences in the telomere of live or fixed human cells (U2OS cells; Ma, H. et al., 2013b). A specific chromosome was identified using centromeric repeat sequences specific to the particular chromosome (Ma, H. et al., 2013b). Miyanari et al. used TALE-FP to show that paternal and maternal chromosomes could be differentially labeled and visualized in live mouse cells and embryos using single nucleotide polymorphisms (SNPs) in the chromosomes due to the extreme sequence specificity of TALEs (Miyanari et al., 2013). Using a dCas9 system fused to fluorescent proteins and capitalizing on the strength of the CRISPR/dCas9 system for multiplexing, Chen et al. visualized non-repetitive genomic sequences by “tiling” sgRNA along the target locus (Chen et al., 2013). All three studies imaged changing chromosomal organizations at each cell cycle. It is not known whether and how post-mitotic neurons change genomic conformation. The three studies indicate that the structural and organizational understanding of the genome in neurons could be done in vivo.

**OFF-TARGET EFFECTS**

In each application of PDBAs, a strategy to identify off-target effects needs to be in place. Despite the precision that the PDBA systems have shown, it is imprudent to expect any PDBA to bind to one unique locus in the genome. Plant pathogenic bacteria in the genus *Xanthomonas* evolved type III secretion system delivering TALEs into plant cells to induce expression of the host genes beneficial to their survival (Yang and White, 2004; Gu et al., 2005). Several off-targets in DNA binding would not have compromised the purpose of the system. When bacteria detect foreign viral DNA sequences registered in their CRISPR sequences (Ishino et al., 1987; Barrangou et al., 2007; Garneau et al., 2010), a few mismatches might be tolerated as far as the exogenous DNAs are effectively cleaved in the
same way the restriction endonuclease system has evolved in bacteria. Thus, the specificity of targeting a locus in the genome is a primary concern that arises with the adaptation of the biological systems to human needs, in particular, for therapeutic purposes. In most research systems, off-target effects of PDBAs can be ruled out by generating two independent mutant alleles in which a genotype-phenotype relationship is confirmed. In animal models, potentially undetected off-target effects can be diluted out through chromosomal shuffling during meiosis. In cell culture models, two clones with the same mutation can be chosen to ensure the phenotype appears due to the mutation. With therapeutic and clinical applications, the system needs to be highly specific. If a PDBA system is used somatically to alter DNA sequences in differentiated adult cells, the change is permanent in the individual. In germ-line applications, the changes to the genetic material are permanent and inheritable. These serious implications in clinical applications need to be considered, but it is equally important to see that there are different levels of stringency for precision depending on the nature of the experiments planned. Therefore, for researchers who plan to use a PDBA system, their experimental purposes are the most important consideration when choosing a PDBA system. For genome engineering as a discipline, researchers have most intensely investigated two areas as they aim to develop therapies with PDBAs: one to improve the specificity of the system and the other to detect off-target sites and effects.

Statistically, a CRISPR/Cas or TALE (monomer with 15-RVDs) system can incur off-target effects (cleavage or altered expression), although a TALEN (15-RVDs × 2) system may offer unique binding even in large mammalian genomes including the human’s. An sgRNA in the CRISPR/Cas system can encounter a binding sequence by chance every 4^{12} bases (≈1.5 × 10^7) to 4^{14} bases (≈2.5 × 10^8), taking into account two specific nucleotides in the PAM sequence (nGG) and 10–12 nt of seed sequences immediately upstream of the PAM sequence within a 20-nt sgRNA. This results in 11–179 potential binding sites in a human haploid genomic sequence (≈3 gigabases) assuming random genomic sequences. Mismatches are tolerated even in the seed sequences in the sgRNA, which increases the chance of off-target binding of Cas9 further. A 15-RVD based and dimerized TALEN system would encounter a binding site every 4^{30} bases (≈1.0 × 10^{18}), which suggests the possibility of a unique target site in the human haploid genome. However, since the binding of each RVD is not completely exclusive to one nucleotide, TALENs also have detectable off-target effects (Hockemeyer et al., 2011; Fine et al., 2014).

Statistical probability notwithstanding, experimentally-determined data on off-target effects of the CRISPR/Cas system have been different from that of bioinformatics predictions. Methods to identify off-target effects have evolved from sequence-based computational prediction to genome-wide identification of Cas9-binding sites with chromatin immunoprecipitation (ChIP), and later to genome-wide interrogation of DNA cleavage (for a review, see Ishida et al., 2015; Koo et al., 2015; O’Geen and Yu, 2015). Sequenced genomes allow direct comparison of the nucleotide sequences of designed sgRNAs, identifying predictable off-target binding sites. This bioinformatic identification of off-target sites was the basis of early studies in which these selected sites were monitored with reporter systems and sequenced (Cradick et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013; Mali et al., 2013a; Cho et al., 2014; Fu et al., 2014). The off-target binding and DNA cleavage resulting from these studies varied widely—depending on the target site and sgRNAs—from no off-target sites to ∼10 sites for each sgRNA. It is not clear if this is a site-specific epigenetic environmental effect, sgRNA sequence effect, or something else. After this selected investigation of off-target effects, more unbiased approaches were developed. These investigations utilized RNA sequencing (Gilbert et al., 2013; Perez-Pinera et al., 2013a) or ChIP followed by sequencing (Cencic et al., 2014; Kusc et al., 2014; Wu et al., 2014; Polstein et al., 2015). To investigate the binding of Cas9 protein to the target locus, a modified version of dCas9 was used with ChIP-seq applications. It was hypothesized that since dCas9 does not cleave the DNA and stays bound, it would generate unbiased genome-wide snapshots unmasked by potentially varying efficiency of DNA repair in different cell lines. The majority of the studies found a highly enriched binding to the target sites and highly specific gene expression patterns (0 or 1 off-target binding sites), yet there was identifiable off-target binding (up to a few hundred sites) for some sgRNAs as well. These methods presented two challenges. First, it was difficult to functionally determine if the binding of dCas9 changed gene expression since sequence mutations were absent. A threshold has to be arbitrarily set to interpret if the changes in gene expression were significant. Second, this method also captured transient binding of dCas9 to the genomic DNA. The mechanism of Cas9-DNA binding suggests that Cas9 scans the genome for the PAM sequence (5′-NGG-3′) and that there is transient binding depending on the degree of sequence matching between the sgRNA and genomic DNA sequence (Anders et al., 2014). Thus, the off-target binding of dCas9 might not be off-target events but merely the locus of dCas9 at the moment of the assay.

Overcoming these limitations, unbiased DNA cleavage event-based methods were developed. These methods integrate DNA double-strand break (DSB) events with insertion of reporters or capturing of the broken fragments with adaptors. IDLV (integrase-defective lentiviral vector), GUIDE (genome-wide, unbiased identification of DSBs enabled by sequencing), and BLESS (direct in situ breaks labeling, enrichment on streptavidin and stays bound) are methods make use of lentivirus integration, double-strand oligo deoxyribonucleotide (dsODN), or streptavidin as a DSB capture device, respectively (Tsai et al., 2014b; Ran et al., 2015; Wang et al., 2015). While the strength of these methods is that DNA DSBs are captured, their shortcoming is that it might capture DSB events that are independent of PDBA-induced breaks. More recently, two technologies provided an improved way of identifying PDBA activities. O’Geen et al. co-opted a ChIP-seq based method to enrich significant dCas9-binding signal by designing capture probes (O’Geen et al., 2015). Kim et al. developed a system to identify off-targets without any capture devices by re-digesting Cas9-treated genomic DNA with Cas9 in vitro (Kim et al., 2015). These unbiased approaches find that CRISPR/Cas systems are specific, making one off-target
cut in the whole genome when appropriately designed sgRNAs were used (O’Geen et al., 2015). For an sgRNA to be deemed appropriately designed, the sgRNA has to be unique in the genome by more than four nucleotides compared to potential off-target sites. However, there are cases of sgRNAs that led to several tens off-target sites despite the apparent soundness of the design (Tsai et al., 2014b; Kim et al., 2015; Ran et al., 2015; Wang et al., 2015). In addition, these methods confirmed that computational sequence predictions are different from actual off-target cleavage sites and that dCas9-binding sites are different from actual off-target cleavage sites. Some reasons for the differences identified are sequence variation in the sample (Yang et al., 2014) and DNA or sgRNA bulging at the target sites (Lin et al., 2014). These studies demonstrate that while CRISPR/Cas systems have clear off-targeting effects, they rarely have the spurious off-target sites that bioinformatic methods predicted. However, further optimization is absolutely required to adapt CRISPR/Cas systems for therapeutic purposes, as zero off-target sites is the expectation for clinical applications.

Efforts to increase the specificity of CRISPR/Cas9 systems have attempted various strategies. Optimized sgRNA designs such as shorter sgRNAs (17–18 nts) truncated at the 5′-end of conventional 20 nt sgRNAs (Fu et al., 2014) or addition of two guanine nucleotides at the 5′-end of sgRNAs (Cho et al., 2014) significantly decreased off-target effects. Cas9 has been engineered to make Cas9 variants with either endonuclease domain, RuvC or HNH, inactivated (Jinek et al., 2012). A pair of Cas9 nickases targeted to adjacent sites on opposite strands results in DNA DSBs with significantly reduced off-target effects (Ran et al., 2013; Mali et al., 2013a; Cho et al., 2014; Frock et al., 2014; Shen et al., 2014). In a similar pairing scheme, a dCas9 protein with nuclease domains inactivated is fused to FokI endonuclease, as FokI dimerization is required to make DNA DSBs. The dCas9-FokI systems showed significantly improved specificity (Tsai et al., 2014a; Guilinger et al., 2014b; Wyvekens et al., 2015). A disadvantage of nickase and dCas9-FokI systems is that the pairing requirement decreases the number of available target sites in a genome since two closely located PAM sequences are needed.

Most recently, two groups independently reported engineered S. pyogenes Cas9 (SpCas9) systems that show significantly decreased off-target effects using current unbiased genome-wide off-target screening technologies. Both groups optimized the energetics during the formation of target DNA-guide RNA-SpCas9 complex by decreasing non-specific interactions between SpCas9 protein and target DNA while maintaining specific interactions between guide RNA and the complementary strand of target DNA (Kleinstiver et al., 2016; Slaymaker et al., 2016). Slaymaker et al. focused on the non-specific electrostatic interactions between the negatively charged phosphate backbone of the non-complementary strand of target DNA and the positively charged amino acid residues in SpCas9 protein in the groove between two nuclease domains (Slaymaker et al., 2016). Three engineered SpCas9 variants [SpCas9 (K855A), eSpCas9(1.0) (K810A/K1003A/R1060A), and eSpCas9(1.1) (K848A/K1003A/R1060A)] showed undetectable off-target effects at three previously identified off-target sites using next generation sequencing in human cell cultures (Slaymaker et al., 2016). When all known off-target sites were investigated, eSpCas9(1.0) and eSpCas9(1.1) showed a significantly decreased cleavage rate (<0.2% indel) in 22 out of 24 sites. In BLESS assessments for unbiased genome-wide off-target screening, there were still noticeable indels while reduction in off-target cleavage was clear compared to wild-type Cas9. BLESS only detected 1.0 and 0.7% indels at two EMX1(1) off-target sites (OTs) and 2.5, 6.3, 14.7, and 25.5% at four VEGFA(1) OTs for SpCas9 (K855A). eSpCas9(1.1) showed no discernible indels at EMX1(1) and 0.3 and 27.0% indels at two VEGFA(1) OTs. The three SpCas9 variants [SpCas9 (K855A), eSpCas9(1.0), and eSpCas9(1.1)] maintained on-target indel efficiency comparable (30–160%) to wild-type SpCas9 assessed with 24 sgRNAs in 10 endogenous loci (Slaymaker et al., 2016).

While Slaymaker et al. focused on non-complementary DNA strand and electrostatic interactions, Kleinstiver et al. engineered the Cas9 amino acid residues that make non-specific contact with complementary DNA strand to sgRNA through hydrogen bonds (Kleinstiver et al., 2016). Kleinstiver et al. abrogated hydrogen bonding between the Cas9 residues (N497, R661, Q695, and Q926) and the phosphate backbone of the complementary strand of target DNA by replacing those residues with alanine residues. When assessed with GUIDE-seq for unbiased genome-wide off-target detection, the Cas9 variant, SpCas9-HF1, with all four residues replaced with alanine, showed a complete absence of off-target effects with seven sgRNAs in four endogenous loci in human cells and only one detectable off-target effect. Subsequent next generation sequencing of 36 wild-type Cas9 OTs identified in GUIDE-seq showed that SpCas9-HF1 had only a background level of indels at 34 out of 36 OTs and negligible indel rates of 0.049 and 0.037% at the other two OTs (Kleinstiver et al., 2016). SpCas9-HF1 maintained on-target mutagenic efficiency comparable (70–140% excluding one sgRNA with no activity) to wild-type Cas9 with 12 sgRNAs in five endogenous loci (Kleinstiver et al., 2016).

The differences in off-target effects between the two structure-guided protein engineering studies might come from varying sensitivity of genome-wide screening technologies (BLESS vs. GUIDE-seq). Importantly, these two studies demonstrated that rational protein engineering can improve specificity in CRISPR/Cas systems. Along with off-target detecting techniques and engineered Cas9 proteins, sgRNA designing software is evolving, which may further decrease off-target effects through design of higher-specificity sgRNAs (Bae et al., 2014b; Montague et al., 2014; Xie S. et al., 2014b; Moreno-Mateos et al., 2015).

Although statistics and bioinformatics predict that TALENs are highly specific, TALENs also have off-target effects. With optimization of the system, the number of off-target sites have significantly decreased (Osborn et al., 2013; Ousterout et al., 2013; Guilinger et al., 2014a). A study showed that the 5′-side of TALEN-binding site (N-term side of TALENs) is more influential in determining TALEN specificity and found that for higher activity and specificity, the first two bases should not be adenine-adenine or cytosine-adenine (Meckler et al., 2013; Juillerat et al., 2014). The degree of individual RVD specificity was also studied. All classic RVDs (NI:A, HD:C, NNI:G, and NG:T)
do not bind exclusively to one base; rather, RVDs have degrees of discriminating power among the four bases rather than an RVD exclusively binds to a base. For example, HD conventionally binds to cytosine (C) and discriminates C from adenine, guanine, and thymine with scores of 0.06, 0.80, and 0.47, respectively (where 1.00 represents perfect discrimination; Juillerat et al., 2015). This limited specificity led to the development of non-conventional RVDs to improve the specificity of TALENs targeting the same locus. In a different approach using modified phage display and protein evolution systems, Hubbard et al. developed a directed protein evolution system in which the DNA binding domain of TALENs can be rapidly optimized for an improved specificity (Hubbard et al., 2015). It is now critical to apply unbiased genome-wide screening developed for CRISPR/Cas9 systems to TALEN off-target screening to validate that directed protein evolution and non-conventional RVDs do indeed decrease off-target effects.

Acknowledging that none of the PDBAs are absolutely specific is important because it will facilitate investigations to improve specificity and detect off-target effects. As a practical guideline, any investigation using PDBAs should use an alternative design (two target sites against a locus) to show the genotype-phenotype relationship beyond doubt. In addition, large-scale projects should be mandated to employ at least one unbiased off-target screening method to show that the PDBA used is reasonably specific without any spurious off-target effects. Lastly, if the system is an animal model, F2 or later generations rather than F1s should be used to ensure the dilution of non-specific mutagenesis. If enough cautions are used, PDBAs are already precise enough to accommodate most (if not all) of research needs. For therapeutic applications, any PDBA systems will need to be further optimized. However, if the absence of off-target effects is shown in cell culture systems and animal models, the particular PDBA design that targets a specific locus may be tested in human subjects.

CONCLUSIONS AND PERSPECTIVES

New generations of programmable DNA-binding agents (PDBAs) such as TALE and CRISPR/Cas systems have rapidly materialized highly efficient genome engineering systems. PDBAs can now target nearly any locus in the genome, introduce or correct mutations, modulate gene expression, and change epigenetic environments with a controllable level of off-target effects, which provides unprecedented opportunities to understand neuronal and neuropsychiatric disorders. These PDBA technologies are being incrementally introduced in neuroscience, and there are only a small number of investigations that focus on the effects and outcomes of PDBA application in the nervous system. Considering distinctive mechanisms of DNA double-strand break repair and epigenetic regulation in neurons, we need more studies to complete our understanding of the functions and effects of applying PDBAs in the nervous system. To access the central nervous system, delivery mechanisms will need to be further engineered (Holkers et al., 2014; Ain et al., 2015; Chen and Gonçalves, 2015). To achieve cell-line specific inducible PDBA systems, neural populations and cell-line specific promoters need to be better characterized to avoid false outcomes (Forni et al., 2006; Galichet et al., 2010). In spite of these outstanding challenges, PDBAs will be a pivotal technology that will lead to new understanding and drive innovations in neuroscience.

AUTHOR CONTRIBUTIONS

All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

The National Institutes of Health (Grants: GM63904, DK84567), Mayo Graduate School, the Mayo Clinic Center for Individualized Medicine, Sanford Research, and the Mayo Foundation for Medical Education and Research provided funding and support for our work.

ACKNOWLEDGMENTS

We thank J. Mark Curry in Division of Creative Media at the Mayo Clinic for artistic rendition of the figures and Julie A. Swenson at the Mayo Clinic Libraries for library service.

REFERENCES

Ain, Q. U., Chung, J. Y., and Kim, Y.-H. (2015). Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J. Control. Release 209, 120–127. doi: 10.1016/j.jconrel.2014.12.036
Amin, N. D., Bai, G., Klug, J. R., Bonanomi, D., Pankratz, M. T., Gifford, W. D., et al. (2015). Loss of motoneuron-specific microRNA-218 causes systemic neuro muscular failure. Science 350, 1525–1529. doi: 10.1126/science.aad2509
An, M. C., O’Brien, R. N., Zhang, N., Patra, B. N., De La Cruz, M., Ray, A., et al. (2014). Polyglutaminne disease modeling: epistate based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr. 6࢑6currents.6d.0242de2e7ad72225eſa72f6Ed589369a. doi: 10.1371/currents.6d.0242de2e7ad72225eſa72f6Ed589369a
Anders, C., Niewoehner, O., Duerst, A., and Jinek, M. (2014). Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513, 569–573. doi: 10.1038/nature13579
Bae, S., Kweon, J., Kim, H. S., and Kim, J.-S. (2014a). Microhomology-based choice of Cas9 nuclease target sites. Nat. Meth. 11, 705–706. doi: 10.1038/nmeth.3015
Bae, S., Park, J., and Kim, J.-S. (2014b). Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonuclease. Bioinformatics 30, 1473–1475. doi: 10.1093/bioinformatics/btu048
Bai, J., Choi, S.-H., Ponciano, G., Leung, H., and Leach, J. E. (2000). Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr. 6õ6currents.6d.0242de2e7ad72225eſa72f6Ed589369a. doi: 10.1371/currents.6d.0242de2e7ad72225eſa72f6Ed589369a
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moinéau, S., et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712. doi: 10.1126/science.1138140
Bedell, V. M., Wang, Y., Campbell, J. M., Poshusta, T. L., Starker, C. G., Krug, R. G., et al. (2012). In vivo genome editing using a high-efficiency TALEN system. Nature 491, 114–118. doi: 10.1038/nature11537
Benjamin, M. B., and Little, J. B. (1992). X rays induce interallelic homologous recombination at the human thymidine kinase gene. Mol. Cell. Biol. 12, 2730–2738. doi: 10.1128/MCB.12.6.2730

Beumer, K. J., Trautman, J. K., Bozas, A., Liu, J.-L., Rutter, J., Gall, J. G., et al. (2008). Efficient gene targeting in Drosophila by direct embryo injection with zinc-finger nucleases. Proc. Natl. Acad. Sci. U.S.A. 105, 19821–19826. doi: 10.1073/pnas.0810471105

Bibikova, M., Carroll, D., Segal, D. J., Trautman, J. K., Smith, J., Kim, Y.-G., et al. (2001). Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell. Biol. 21, 289–297. doi: 10.1128/MCB.21.1.289-297.2001

Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., and Marraffini, L. A. (2013). Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429–7437. doi: 10.1093/nar/gks520

Bock, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509–1512. doi: 10.1126/science.1178811

Bogdanove, A. J., Schornack, S., and Lahaye, T. (2010). TAL effectors: finding a library of synthetic transcription activator-like effector-based constructs for DNA targeting. Mol. Plant. doi: 10.1101/cshperspect.a012757

Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M., Brodsky, M. H., et al. (2015). DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat. Met. 12, 1150–1156. doi: 10.1038/nmet.3624

Brooks, P. J. (2002). DNA repair in neural cells: basic science and clinical implications. Mutat. Res. 509, 93–108. doi: 10.1016/S0027-5107(02)00222-1

Brückner, K., Schäfer, P., Weber, E., Grützner, R., Marillonnet, S., and Tissier, A. (2015). A library of synthetic transcription activation-like effector-activated promoters for coordinated orthogonal gene expression in plants. Plant J. 82, 707–716. doi: 10.1111/tjp.12843

Bultmann, S., Morbitzer, R., Schmidt, C. S., Thanisch, K., Spada, F., Elsaesser, J., et al. (2012). Targeted transcriptional activation of silent oct4 pluripotency gene using an engineered CRISPR-Cas system. PLoS ONE 7:e45383. doi: 10.1371/journal.pone.0045383

Cong, L., Ran, A. F., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823. doi: 10.1126/science.1231143

Cong, L., Zhou, R., Xiao, C.-Y., Cummis, M., and Zhang, F. (2012). Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat. Commun. 3, 968. doi: 10.1038/ncomms1962

Corti, S., Nizzardo, M., Simone, C., Falcone, M., Nardini, M., Ronchi, D., et al. (2012). Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 4, 165ra162. doi: 10.1126/scitranslmed.3004108

Cradick, T. J., Fine, E. J., Antico, C. J., and Bao, G. (2013). CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584–9592. doi: 10.1093/nar/gkt1714

Crichlow, S. E., and Jackson, S. P. (1998). DNA end-joining: from yeast to man. Trends Biochem. Sci. 23, 394–398. doi: 10.1016/S0968-0004(98)01284-5

Desjarlais, J. R., and Berg, J. M. (1992). Toward rules relating zinc finger protein sequences and DNA binding site preferences. Proc. Natl. Acad. Sci. U.S.A. 89, 7345–7349. doi: 10.1073/pnas.89.16.7345

Ding, Q., Lee, Y.-K., Schaefer, E. A. K., Peters, D. T., Veres, A., Kim, K., et al. (2013a). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238–251. doi: 10.1016/j.stem.2012.11.011

Ding, Q., Regan, S. N., Xia, Y., Oostrom, L. A., Cowan, C. A., and Musunuru, K. (2013b). Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–394. doi: 10.1016/j.stem.2013.03.006

Dunn, E. C., Brown, R. C., Dai, Y., Rosand, J., Nugent, N. R., Amstader, A. B., et al. (2015). Genetic determinants of depression: recent findings and future directions. Harv. Rev. Psychiatry 23, 1–18. doi: 10.1097/HRP.0000000000000054

Evans, M. J., and Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156. doi: 10.1038/292154a0

Fanucchi, S., Shibayama, Y., Burd, S., Weinberg, M. S., and Mhlanga, M. M. (2013). Chromosomal contact permits transcription between coregulated genes. Cell 155, 660–620. doi: 10.1016/j.cell.2013.09.051

Ferguson, C., McKay, M., Harris, R. A., and Homanics, G. E. (2013). Toll-like receptor 4 (Tlr4) knockout rats produced by transpositional activator-like effector nucleic acid (TALEN)-mediated gene inactivation. Alcohol 47, 595–599. doi: 10.1097/ALC.0b013e318295e43

Fine, E. J., Cradick, T. J., Zhao, C. L., Lin, Y., and Bao, G. (2014). An online bioinformatics tool predicts zinc finger and TALE nucleic acid-off-target cleavage. Nucleic Acids Res. 42, e122. doi: 10.1093/nar/gkt1326

Folger, K. R., Wong, E. A., Wahl, G., and Capecchi, M. R. (1982). Patterns of integration of DNA microinjected into cultured mammalian cells: evidence for homologous recombination between injected plasmid DNA molecules. Mol. Cell. Biol. 2, 1372–1387. doi: 10.1128/MCB.2.8.1372

Fong, H., Wang, C., Knofler, J., Walker, D., Balestra, M. E., Tong, L. M., et al. (2013). Genetic correction of taupathy phenotypes in neurons derived from human induced pluripotent stem cell lines. Proc. Natl. Acad. Sci. U.S.A. 110, 20266–20271. doi: 10.1073/pnas.1316425110

Fon, S. W., Kim, S., Kim, Y., Kweon, J., Kim, H. S., Bae, S., et al. (2014). Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132–141. doi: 10.1101/gr.162339.113

Fruh, Y., and Klug, A. (1994). Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. Proc. Natl. Acad. Sci. U.S.A. 91, 11163–11167. doi: 10.1073/pnas.91.23.11163

Choulalka, A., Perrin, A., Dujon, B., and Nicolas, J. F. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. 15, 1968–1973. doi: 10.1128/MCB.15.4.1968

Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., et al. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761. doi: 10.1534/genetics.110.120717

Christiansen, M. L., Demarest, Z. L., Starker, C. G., Osborn, M. J., Nyquist, M. D., Zhang, Y., et al. (2012). Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues. PLoS ONE 7:e45383. doi: 10.1371/journal.pone.0045383

Lee et al. Genome Engineering in Neuroscience
Guilinger, J. P., Pattanayak, V., Reyon, D., Tsai, S. Q., Sanders, J. D., Joung, J. K., et al. (2014a). DNA targeting specificity of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods, 11, 429–435. doi: 10.1038/nmeth.2845

Guilinger, J. P., Thompson, D. B., and Liu, D. R. (2014b). Fusion of catalytically inactive Cas9 to FokI nucleases improves the specificity of genome modification. Nat. Biotechnol. 32, 577–582. doi: 10.1038/nbt.2909

Guo, J., Gaj, T., and Barbash, C. F. (2010). Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J. Mol. Biol. 400, 96–107. doi: 10.1016/j.jmb.2010.04.060

Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S., et al. (2014). CRISPR/Cas9 nucleotide repeat structures initiate molecular cascades of disease. Nature 507, 195–200. doi: 10.1038/nature13124

Hagmann, M., Adikofer, K., Pfiffer, P., Bruggmann, R., Georgiev, O., Rungger, D., et al. (1996). Dramatic changes in the ratio of homologous recombination to nonhomologous DNA-end joining in oocytes and early embryos of Xenopus laevis. Biol. Chem. Hoppe Seyler 377, 239–250. doi: 10.1515/bchm3.1996.777.4.239

He, M.-D., Zhang, F.-H., Wang, H.-L., Wang, H.-P., Zhu, Z.-Y., and Sun, Y.-H. (2015). Efficient ligase 3-dependent microhomology-mediated end joining repair of DNA double-strand breaks in zebrafish embryos. Mutat. Res. 780, 86–96. doi: 10.1016/j.mrfmmm.2015.08.004

Heidenreich, E., Novotny, R., Kneidinger, B., Holzmann, V., and Wintersberger, U. (2003). Non—homologous end joining as an important mutagenic process in cell cycle—arrested cells. EMBO J. 22, 2274–2283. doi: 10.1093/emboj/cgd203

Heller, E. A., Cates, H. M., Peña, C. J., Sun, H., Shao, N., Feng, J., et al. (2014). Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat. Neurosci. 17, 1720–1727. doi: 10.1038/nn.3871

Hilton, I. B., D’Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., et al. (2015). Epigenome editing by a CRISPR-Cas9-based artificial transferrase activates genes from promoters and enhancers. Nat. Biotechnol. 33, 710–717. doi: 10.1038/nbt.3199

Hirschhorn, J. N., and Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95–108. doi: 10.1038/nrg1521

Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C., Soneda, E., Schreiber, V., et al. (2006). Purp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 25, 1305–1314. doi: 10.1038/sj.emboj.7601015

Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassidy, J. P., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731–734. doi: 10.1038/nbt.1927

Holkers, M., Maggio, I., Henningen, S. F. D., Janssen, J. M., Cathomen, T., and Gonçalves, M. A. F. V. (2014). Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat. Meth. 11, 1051–1057. doi: 10.1038/nmeth.3075

Horvath, P., and Barrangou, R. (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167–170. doi: 10.1126/science.1179555

Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., et al. (2013). Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 140, 4982–4987. doi: 10.1242/dev.099085

Hsu, P. D., Scott, D. A., Wei, Z.,UL, Ran, F. A., Konermann, S., Agarwala, V., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832. doi: 10.1038/nbt.2647

Huang, W., Zheng, J., He, Y., and Luo, C. (2013). Tandem repeat modification during double-strand break repair induced by an engineered TAL effector nuclease in zebrafish genome. PLoS ONE 8:e84176. doi: 10.1371/journal.pone.0084176

Hubbard, B. P., Badran, A. H., Zuris, J. A., Guilinger, J. P., Davis, K. M., Chen, L., et al. (2015). Continuous directed evolution of DNA-binding proteins to improve TALEN specificity. Nat. Meth. 12, 939–942. doi: 10.1038/nmeth.3515

Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sanders, J. D., et al. (2013). Efficient genome editing in zebrafish using a CRISPR-Cas9 system. Nat. Biotechnol. 31, 227–229. doi: 10.1038/nbt.2501

Incontro, S., Asensio, C. S., Edwards, R. H., and Nicoll, R. A. (2014). Efficient, complete deletion of synaptic proteins using CRISPR. Neuron 83, 1051–1057. doi: 10.1016/j.neuron.2014.07.043

Ishida, K., Gee, P., and Hotta, A. (2015). Minimizing off-target mutagenesis risks caused by programmable nucleases. IJMS 16, 24751–24771. doi: 10.3390/ijms161024751

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., and Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169, 5429–5433.
Iyama, T., and Wilson, D. M. III (2013). DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). 12, 620–636. doi: 10.1016/j.dnarep.2013.04.015

Jasin, M., and Rothstein, R. (2013). Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol. 5:a012740. doi: 10.1101/cshperspect.a012740

Jiang, F., and Doudna, J. A. (2015). The structural biology of CRISPR-Cas systems. Curr. Opin. Struct. Biol. 30, 100–111. doi: 10.1016/j.sbi.2015.02.002

Jinek, M., Chylinski, K., Fenfara, I., Hauer, M., Doudna, J. A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821. doi: 10.1126/science.1225829

Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., and Doudna, J. (2013). RNA-programmed genome editing in human cells. Elife 2:e00471. doi: 10.7554/eLife.00471

Jo, Y.-I., Kim, H., and Ramakrishna, S. (2015). Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. Cell. Mol. Life Sci. 72, 3819–3830. doi: 10.1007/s00018-015-1956-5

Jones, J. M., and Meisler, M. H. (2014). Modeling human epilepsy by TALEN targeting of mouse sodium channel Scn8a. Genesis 52, 141–148. doi: 10.1002/dvg.22273

Juillerat, A., Dubois, G., Walton, J., Thomas, S., Stella, S., Maréchal, A., et al. (2014). Comprehensive analysis of the specificity of transcription activator-like effector nucleases. Nucleic Acids Res. 42, 5390–5402. doi: 10.1093/nar/gku155

Juillerat, A., Pessereau, C., Dubois, G., Guyot, V., Maréchal, A., Walton, J., et al. (2015). Optimized tuning of TALEN specificity using non-conventional RVDs. Sci. Rep. 5, 8150–8157. doi: 10.1038/srep08150

Kadyk, L. C., and Hartwell, L. H. (1992). Sister chromatids are preferred over homologs as substrates for recombinational repair in Saccharomyces cerevisiae. Genetics 132, 387–402.

Karakesis, I., Stillfrano, F., Nonnenmacher, M., Tizmas, C., Sanoudou, D., Termgl欣chan, V., et al. (2015). Correction of human phospholamban R14del mutation associated with cardiomypathy using targeted nucleases and combination therapy. Nat. Commun. 6, 1–10. doi: 10.1038/ncomms7995

Kay, S., Hahn, S., Marois, E., Hause, G., and Bonas, U. (2007). A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science 318, 648–651. doi: 10.1126/science.1144956

Kearns, N. A., Genga, R. M. J., Enuameh, M. S., Garber, M., Wolfe, S. A., and Maehr, M. (2013). Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development 141, 219–223. doi: 10.1242/dev.103341

Keatinge, M., Bui, H., Menke, A., Chen, Y.-C., Sokol, A. M., Bai, Q., et al. (2015). Glucocerebrosidase I deficient Danio rerio: mirror key pathological aspects of glucocerebrosidase deficiency in human embryonic stem cells. Development and Maehr, R. (2013). Cas9 effector-mediated regulation of transcription and genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nucleic Acids Res. 50, 472–476. doi: 10.1038/nature12466

Kerstens, K., Nian, C., and Lynn, F. C. (2014). TALEN/CRISPR-mediated eGFP knock-in add-on at the OCT4 locus does not impact differentiation of human embryonic stem cells towards endoderm. PLoS ONE 9:e114275. doi: 10.1371/journal.pone.0114275

Kisczens, C., Asrlan, S., Singh, R., Thorpe, J., and Adli, M. (2014). Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 32, 687–683. doi: 10.1038/nbt.2916

Lagneger, J., Kells, A. P., Lai, J. T., Guschin, D., Paschon, D. E., Meng, X., et al. (2010). An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of parkinson’s disease. J. Neurosci. 30, 16469–16474. doi: 10.1523/JNEUROSCI.2440-10.2010

Lee, J. S., Kallehauge, T. B., Pedersen, L. E., and Kildegaard, H. F. (2015). Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Sci. Rep. 5, 8572–8571. doi: 10.1038/srep08572

Lemhan, C. W., Clemens, M., Worthylake, D. K., Trautman, J. K., and Carroll, D. (1993). Homologous and illegitimate recombination in developing Xenopus oocytes and eggs. Mol. Cell. Biol. 13, 6897–6906. doi: 10.1128/MCB.13.11.6897

Lenzi, J. De Santis, R. De, Turrissi, V. Morlando, M., Lanepe, P., Calvo, A., et al. (2015). ALS mutant FUS proteins are recruited into stress granules induced by genetically modified motorneurons. Dis. Model. Mech. 8, 755–766. doi: 10.1242/dmm.020099

Li, D., Qiu, Z., Shao, Y., Chen, Y., Guan, Y., Liu, M., et al. (2013). Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31, 681–683. doi: 10.1038/nbt.2661

Li, J., Shou, J., Guo, Y., Tang, Y., Wu, Y., Jia, Z., et al. (2015). Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9. J. Mol. Cell. Biol. 7, 284–298. doi: 10.1093/jmcb/mjv016

Li, T., Huang, S., Jiang, W. Z., Wright, D., Spalding, M. H., Weeks, D. P., et al. (2011). TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleaveoing domain. Nucleic Acids Res. 39, 359–372. doi: 10.1093/gnarqtl04

Li, Y., Jiang, Y., Chen, H., Liao, W., Li, Z., Weiss, R., et al. (2015). Modular construction of mammalian gene circuits using TALE transcriptional repressors. Nat. Chem. Biol. 11, 207–213. doi: 10.1038/nchembio.1736

Li, Y., Moore, R., Guinn, M., and Bleris, L. (2012). Transcription activator-like effector hybrids for conditional control and rewiring of chromosomal transgene expression. Sci. Rep. 2, 1–7. doi: 10.1038/srep00897

Li, D., Deng, L., Nguyen, S. C., Zhao, X., Maulon, C. D., Shao, C., et al. (2008). Human DNA ligases I and III, but not ligase IV, are required for microhomology-mediated end joining of DNA double-strand breaks. Nucleic Acids Res. 36, 3297–3310. doi: 10.1093/nar/gkn184

Lieber, M. R. (2010). The mechanism of double-strand DNA break repair by the homologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181–211. doi: 10.1146/annurev.biochem.052308.093131

Lieberman-Aiden, E., van Berkum, N. L., Williams, L., Imakaev, M., Ragoczy, T., Telling, A., et al. (2009). Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289–293. doi: 10.1126/science.1181369

Lin, Y., Cradic, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N., et al. (2014). CRISPR/Cas9 systems have off-target activity with insertions or
